Shopping Cart
- Remove All
Your shopping cart is currently empty
(82)
Angiogenesis Filter
Angiogenesis Tyrosine Kinase/AdaptorsACK1
(6)
ALK
(82)
BTK
(98)
Bcr-Abl
(90)
CSF-1R
(20)
DYRK
(32)
Discoidin Domain Receptor (DDR)
(12)
EGFR
(406)
Ephrin Receptor
(23)
FAK
(62)
FGFR
(148)
FLT
(119)
HER
(47)
Hck
(5)
IGF-1R
(67)
IGF-2R
(2)
JAK
(205)
PDGFR
(121)
PKA
(78)
PYK2
(10)
ROS Kinase
(25)
Src
(138)
Syk
(39)
TAM Receptor
(53)
Tie-2
(11)
Trk receptor
(65)
Tyrosine Kinases
(64)
VEGFR
(280)
c-Fms
(50)
c-Kit
(92)
c-Met/HGFR
(113)
c-RET
(43)
Src
Src kinase family is a family of non-receptor tyrosine kinases that includes nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. Frk has homologs in invertebrates such as flies and worms, and Src homologs exist in organisms as diverse as unicellular choanoflagellates, but the SrcA and SrcB subfamilies are specific to vertebrates. Src family kinases contain six conserved domains: a N-terminal myristoylated segment, a SH2 domain, a SH3 domain, a linker region, a tyrosine kinase domain, and C-terminal tail.
Staurosporine
T668062996-74-1
Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6 15 2 3 3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
Size
QTY
Saracatinib
T6078379231-04-6
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
- $59
Size
QTY
Nintedanib
T1777656247-17-5
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34 13 13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69 37 108 nM), PDGFRα, and PDGFRβ (IC50=59 65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
- $38
Size
QTY
eCF506
T84991914078-41-3
eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)
- $40
Size
QTY
Ibrutinib
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
Tofacitinib
T6321477600-75-2
Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3 2 1 (IC50=1 20 112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.
- $30
Size
QTY
Vemurafenib
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31 48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
Dasatinib
T1448302962-49-8
Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16 30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.
- $37
Size
QTY
Ponatinib
T2372943319-70-8
Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor with IC50 values of 0.37 nM (Abl), 1.1 nM (PDGFRα), 1.5 nM (VEGFR2), 2.2 nM (FGFR1), and 5.4 nM (Src).
- $37
Size
QTY
BGB-102
T10531807640-87-5
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
- $328
Size
QTY
Bafetinib
T6311859212-16-1
Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl Lyn inhibitor (IC50: 5.8 19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.
- $31
Size
QTY
NVP-BHG712
T6348940310-85-0
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
- $30
Size
QTY
A 419259 trihydrochloride
TQ01321435934-25-0In house
A 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).
- $48
Size
QTY
SGI-7079
T69821239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
- $35
Size
QTY
Rebastinib
T26401020172-07-9
DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
- $40
Size
QTY
PD173074
T2642219580-11-7
PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
- $36
Size
QTY
Bosutinib
T0152380843-75-4
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
- $33
Size
QTY
TG 100801
T13157867331-82-6In house
TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).
- $84
Size
QTY
Tirbanibulin
T6345897016-82-9
Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.
- $30
Size
QTY
Repotrectinib
T40711802220-02-5
Repotrectinib (TPX-0005) is a potent ALK ROS1 TRK inhibitor, with IC50 values of 1.01 nM for WT ALK, 5.3 nM for SRC, 1.08 nM for ALK L1196M, and 1.26 nM for ALK G1202R.
- $45
Size
QTY
Fenlean
T31773863193-70-8In house
Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.
- $119
Size
QTY
PP2
T6266172889-27-9
PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck Fyn (IC50:4 5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
- $39
Size
QTY
Dasatinib monohydrate
T1448L863127-77-9
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
- $33
Size
QTY
Lyn-IN-1
T11916887650-05-7
Lyn-IN-1 (Bafetinib analog) is a selective, potent dual inhibitor of Bcr-Abl and Lyn.
- $39
Size
QTY
Go to page 1
Page of 3
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.